PAN-CHINA Certified Public Accountants 关于中化蓝天集团有限公司 资产交割过渡期合并利润表的 专项审计报告 PAN-CHINA 天健会计师事务所 Pan-China Certified Public Accountants 资产交割过渡期合并利润表的专项审计报告 天健审〔2024〕10595 号 昊华化工科技集团股份有限公司: 一、审计意见 我们接受贵公司委托,审计了中化蓝天集团有限公司(以下简称中化蓝天公 司）2023年１月１日至 2024年７月 18 日的资产交割过渡期合并利润表〈以下 简称过渡期合并利润表),以及过渡期合并利润表附注。 我们认为,后附的过渡期合并利润表在所有重大方面按照过渡期合并利润表 附注三所述的编制基础编制, 公允反映了中化蓝天公司在过渡期 2023 年 1 月 1 日至 2024 年 7 月 18 日的经营成果。 ■ 景 | 一、专项审计报告 第 1-4 页 | | --- | | 二、资产交割过渡期合并利润表 | | 三、资产交割过渡期合并利润表附注………………………………………… 第 6―35 页 | | ················· ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2024-077 昊华化工科技集团股份有限公司 关于公司发行股份购买资产并募集配套资金暨关联交易 之标的资产过渡期间损益情况的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昊华化工科技集团股份有限公司（以下简称"公司"或"上市公司"）以发行股 份的方式购买中国中化集团有限公司（以下简称"中化集团"）、中化资产管理有限 公司（以下简称"中化资产"）所持中化蓝天集团有限公司（以下简称"中化蓝天" 或"标的公司"）合计 100%股权（以下简称"标的资产"），同时拟向包括中国对 外经济贸易信托有限公司、中化资本创新投资有限公司在内的不超过 35 名符合条件 的特定投资者非公开发行股份募集配套资金（以下简称"本次交易"）。 2024 年 6 月 20 日，中国证券监督管理委员会已出具《关于同意昊华化工科技集 团股份有限公司发行股份购买资产并募集配套资金注册的批复》（证监许可〔2024〕 964 号），同意本次交易的注册申请。截至 2024 年 7 月 18 日，中化集团持 ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2024-075 昊华化工科技集团股份有限公司 2024 年前三季度主要经营数据公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昊华化工科技集团股份有限公司（以下简称"公司"）根据《上海 证券交易所上市公司自律监管指引第 3 号——行业信息披露》及附件 《第十三号——化工》要求，现将公司 2024 年前三季度主要经营数 据披露如下： 说明：氟化锂受锂电市场需求不足影响，价格大幅下滑；烟片胶受东南亚停割期 和台风影响，采购价格增幅较大。 主要产品 2024 年 1-9 月平均 售价（元/吨） 2023 年 1-9 月平均 售价（元/吨） 变动比率（%） 氟碳化学品 29,896.48 25,583.71 16.86% 含氟锂电材料 24,216.20 37,043.58 -34.63 含氟聚合物 39,669.81 45,297.80 -12.42 含氟精细化学品 45,568.93 56,266.19 -19.01 含氟气体 94,400.30 107,781.6 ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2024－074 昊华化工科技集团股份有限公司 第八届董事会第二十一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昊华化工科技集团股份有限公司（以下简称"公司"或"昊华科 技"）第八届董事会第二十一次会议于 2024 年 10 月 29 日以通讯表 决的方式召开。会议通知等材料已于 2024 年 10 月 21 日以电子邮件 并短信通知的方式发送给公司董事、监事、高级管理人员。会议应出 席董事 9 名，实际出席董事 9 名，共收回有效表决票 9 份。会议的召 开符合相关法律、行政法规、部门规章、规范性文件和《公司章程》 的规定。 会议审议并通过如下议案： 一、关于审议《公司 2024 年第三季度报告》的议案 董事会同意《公司 2024 年第三季度报告》。 公司董事会审计委员会已审议通过相关议案。 表决结果：9 票同意，0 票反对，0 票弃权。 《昊华科技 2024 年第三季度报告》详见 2024 年 10 月 31 日上海 证券交易所网站（www.ss ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2024-076 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 昊华化工科技集团股份有限公司 重要内容提示： 投资者可于 2024 年 11 月 8 日（星期五）至 11 月 14 日（星期 四）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或 通过公司邮箱 hhkj@sinochem.com 进行提问。公司将在说明会上 对投资者普遍关注的问题进行回答。 昊华化工科技集团股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布《昊华科技 2024 年第三季度报告》。为便于广大投资 者更全面、更深入地了解公司 2024 年第三季度经营成果、财务状况， 公司计划于 2024 年 11 月 15 日（星期五）上午 10:00-11:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次业绩说明会以网络互动形式召开，公司将针对 2024 年第三 会议召开时间 ...

Financial Performance - The company's operating revenue for Q3 2024 was approximately CNY 3.67 billion, a decrease of 2.02% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2024 was approximately CNY 315.18 million, an increase of 53.40% year-on-year[4]. - The basic earnings per share for Q3 2024 was CNY 0.2862, reflecting a 53.38% increase compared to the previous year[4]. - The net profit attributable to shareholders for the year-to-date period decreased by 18.60% compared to the same period last year, totaling approximately CNY 851.14 million[4]. - Total operating revenue for the first three quarters of 2024 was CNY 10,207,054,524.59, a decrease of 11.6% compared to CNY 11,548,377,736.51 in the same period of 2023[23]. - Net profit for the first three quarters of 2024 was CNY 890,814,058.88, a decline of 14.7% from CNY 1,044,765,679.89 in the same period of 2023[25]. - Earnings per share for the first three quarters of 2024 were CNY 0.7705, down from CNY 0.9451 in 2023, indicating a decrease of 18.5%[26]. - The company reported a net profit of 368 million CNY in the first three quarters of 2024, representing a year-on-year growth of 61.68%, with a comprehensive gross margin increase of 4.18 percentage points[16]. - In Q3 2024, the company achieved a net profit of 176 million CNY, a quarter-on-quarter increase of 13.98%[16]. Asset and Liability Management - Total assets at the end of the reporting period were approximately CNY 25.39 billion, an increase of 2.80% from the previous year[5]. - The company's total equity reached CNY 12,900,488,746.90 by the end of Q3 2024, compared to CNY 12,227,879,061.00 in the previous year, marking an increase of 5.5%[22]. - Total liabilities as of the end of Q3 2024 amounted to CNY 13,195,009,586.21, slightly up from CNY 13,157,697,326.70 at the end of Q3 2023[22]. - Non-current liabilities increased to CNY 3,682,697,874.68 in Q3 2024 from CNY 3,242,007,888.76 in Q3 2023, representing a growth of 13.6%[22]. Cash Flow Analysis - The net cash flow from operating activities for the year-to-date period decreased by 54.84% to approximately CNY 382.69 million[4]. - In the first three quarters of 2024, the company generated cash inflows from operating activities totaling ¥9,887,600,984.75, a decrease of approximately 9.9% compared to ¥10,977,413,826.57 in the same period of 2023[27]. - The net cash flow from operating activities for the first three quarters of 2024 was ¥382,687,596.59, down 54.9% from ¥847,479,094.95 in the previous year[28]. - The company reported cash outflows from investing activities of ¥1,550,737,093.62, an increase from ¥1,342,130,227.10 in the same period of 2023[28]. - The net cash flow from investing activities was -¥1,442,881,798.08, compared to -¥316,260,606.06 in the previous year, indicating a significant increase in cash outflow[28]. - Cash inflows from financing activities amounted to ¥7,465,222,208.81, up from ¥4,322,745,573.82 in the same period of 2023[28]. - The company's cash and cash equivalents at the end of the period were ¥1,733,630,163.24, down from ¥2,630,580,114.23 at the end of the same period in 2023[29]. - The company experienced a negative net increase in cash and cash equivalents of -¥1,071,456,294.67 for the first three quarters of 2024, compared to -¥298,954,472.90 in the previous year[29]. Acquisitions and Business Development - The company completed the acquisition of 100% equity in Sinochem Blue Sky Group, which has been consolidated into the company's financial statements since July 2024[6]. - The company completed the acquisition of 100% equity in Zhonghua Lantian, enhancing overall profitability and optimizing business structure[12]. - For the first nine months of 2024, the company achieved a revenue of 10.207 billion RMB, with Zhonghua Lantian contributing 4.946 billion RMB, representing a 93.96% increase compared to before the acquisition[14]. - The net profit attributable to shareholders for the first nine months was 851 million RMB, with Zhonghua Lantian contributing 328 million RMB, marking a 62.82% increase compared to before the acquisition[14]. - In Q3 2024, the company reported a revenue of 3.670 billion RMB, with Zhonghua Lantian contributing 1.814 billion RMB, reflecting a 95.32% increase compared to before the acquisition[14]. - The net profit attributable to shareholders in Q3 reached 315 million RMB, with Zhonghua Lantian contributing 163 million RMB, showing a 105.31% increase compared to before the acquisition[14]. Operational Efficiency and Market Outlook - The comprehensive gross profit margin improved significantly due to the successful implementation of cost reduction and efficiency enhancement measures[9]. - The company's overall gross margin improved by 1.06 percentage points year-on-year in Q3 2024, with a net profit growth of 53.40% year-on-year[15]. - The company reported a 2.02% slight decline in revenue year-on-year for Q3, but the integration of Zhonghua Lantian led to significant improvements in profitability[15]. - The company remains confident in the macroeconomic environment, aiming to leverage internal efficiency and external market potential for high-quality development[13]. - The company plans to accelerate major project construction and enhance internal efficiency to achieve annual operational goals[19]. Shareholder Information - The company has a total of 14,240 common shareholders at the end of the reporting period, with the largest shareholder holding 53.23% of the shares[11]. - The company’s major shareholders include state-owned enterprises, with significant shareholdings and some shares under judicial freeze[11]. Research and Development - The company applied for a total of 228 patents in the first nine months of 2024, including 172 invention patents[18].

证券代码：600378 证券简称：昊华科技 昊华化工科技集团股份有限公司 机构投资者调研记录 （2024 年 9 月 1 日-2024 年 10 月 21 日） 1. 调研时间：2024 年 9 月 1 日-2024 年 10 月 21 日 2. 调研地点：北京及线上 3. 调研形式：现场调研、线上交流 | --- | |----------------------------------------------------------| | | | 4. 机构名称 ：华夏基金、山证化工、国信证券、恒大人寿、 | | 国寿养老、健顺投资、长城财富保险、华宝基金、招商 | | 基金、淡水泉基金、开源证券、申万投资、中金公司 | | （资管）、大成基金、中欧基金、太平基金、长城财富 | | 资管、东海基金、瑞信致远基金、玄卜投资、信银理财、 | | 红杉资本、 Brilliance 才华资本、华夏久盈基金、新华基 | | 金、中国人寿资产、华泰资产、泰康资产、兴证全球基 | | 金、循远资产、朱雀基金、北京和聚私募基金、中国人 | | 寿养老保险、中国人寿资产、海南君阳私募基金、中海 | | 基金、交银理财、中科 ...

中国北京建国门外大街 1 号国贸写字楼 2 座 12-14 层 100004 12-14th Floor, China World Office 2, No. 1 Jianguomenwai Avenue, Beijing 100004, China 电话 Tel: +86 10 6563 7181 传真 Fax: +86 10 6569 3838 电邮 Email: beijing@tongshang.com 网址 Web: www.tongshang.com 北京市通商律师事务所 关于昊华化工科技集团股份有限公司2019年限制性股票 激励计划回购注销部分限制性股票实施情况 3.公司及相关公司、相关人员向本所及本所律师作出的书面陈述、说明、确认 和承诺均为真实、准确、全面和完整的，不存在任何虚假、重大遗漏、误导； 4.公司向本所及本所律师提供的文件资料，均与公司自该等文件资料的初始提 供者处获得的文件资料一致，未曾对该等文件资料进行任何形式上和实质上的更改、 删减、遗漏和隐瞒，且已按本所及本所律师合理的要求向本所及本所律师提供或披 露了与该等文件资料有关的其他辅助文件资料或信息，以避免本所及本所律师因该 等 ...

证券代码：600378 证券简称：昊华科技 公告编号：临 2024-073 昊华化工科技集团股份有限公司 股权激励限制性股票回购注销实施公告 年 5 月 16 日在上海证券交易所网站（www.sse.com.cn）及指定披露媒体刊登的 《昊华化工科技集团股份有限公司 2019 年年度股东大会决议公告》（公告编号： 临 2020-029）。 2024 年 8 月 29 日，公司第八届董事会第十九次会议及第八届监事会第十六 次会议审议通过了《关于审议调整公司 2019 年限制性股票激励计划回购价格的 议案》《关于审议回购注销公司 2019 年限制性股票激励计划部分限制性股票的 议案》，同意回购注销 233 名激励对象已获授但尚未解除限售的限制性股票合计 164,681 股，具体内容详见公司于 2024 年 8 月 31 日在上海证券交易所网站 （www.sse.com.cn）及指定披露媒体刊登的《昊华化工科技集团股份有限公司关 于调整公司 2019 年限制性股票激励计划回购价格的公告》（公告编号：临 2024-061）《昊华化工科技集团股份有限公司关于回购注销 2019 年限制性股票 激励计划部分限制性股票的公告 ...

Investment Rating - The report assigns a "Buy-B" rating for the company, indicating a positive outlook for its stock performance in the coming months [1][3]. Core Views - The fluorochemical cycle is at a bottoming phase, and the acquisition of Zhonghua Lantian enhances the company's fluorine industry layout [1]. - The company is expected to improve its core competitiveness and industry influence through independent innovation in key technologies [3]. Financial Performance - In the first half of 2024, the company achieved a revenue of 3.459 billion yuan, a year-on-year decrease of 19.63% [4]. - The net profit attributable to shareholders was 370 million yuan, down 26.32% year-on-year [4]. - The gross margin for the first half was 27.45%, an increase of 2.88 percentage points year-on-year, while the net margin was 10.71%, a decrease of 0.97 percentage points year-on-year [2][4]. Market Data - As of October 8, 2024, the closing price was 32.67 yuan, with a market capitalization of 36.223 billion yuan [3]. - The company has a circulating A-share market value of 29.751 billion yuan and a total share capital of 1.109 billion shares [3]. Future Earnings Estimates - The expected earnings per share (EPS) for 2024, 2025, and 2026 are projected to be 0.97 yuan, 1.48 yuan, and 1.88 yuan, respectively [3]. - The corresponding price-to-earnings (P/E) ratios for these years are estimated at 33.8, 22.1, and 17.4 [3]. Strategic Developments - The company completed the acquisition of Zhonghua Lantian, which is now a wholly-owned subsidiary, and plans to invest up to 4.5 billion yuan in various fluorochemical projects [3]. - The company aims to enhance its fluorochemical segment and improve synergy effects through these investments [3].